HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
Status:
Unknown status
Trial end date:
2020-10-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion
chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus toripalimab versus hepatic
arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus sorafenib
in patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombus.